Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Richard G. Hahn"'
Autor:
Robert T. Eagan, Harry F. Bisel, Jesse L. Steinfeld, John H. Edmonson, David L. Ahmann, William R. Taylor, Richard G. Hahn, Douglass C. Tormey
Publikováno v:
Cancer. 36:1925-1935
Ninety patients with advanced breast cancer received a polychemotherapeutic program composed of 5-fluorouracil, cyclophosphamide, and prednisone with or without vincristine as a control group in a series of four consecutive Phase II clinical trials o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf9177f528f41542432f8931c3f96c10
https://doi.org/10.1002/cncr.2820360601
https://doi.org/10.1002/cncr.2820360601
Autor:
Myrto Lefkopoulou, Paul J. Catalano, Minaxi Jhawer, Daniel G. Haller, Richard G. Hahn, Jules E. Harris, Sridhar Mani
Publikováno v:
Investigational New Drugs. 24:447-454
Metastatic anal cancer is a rare disease in the Western hemisphere and current treatment modalities are not effective. In this study, patients with advanced epithelial cancer of the anal canal received MAP followed by Bleomycin and CCNU upon progress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8de77859af6ca945efb823e5a15d0be
https://doi.org/10.1007/s10637-006-7667-x
https://doi.org/10.1007/s10637-006-7667-x
Phase II study of ?2 interferon in the treatment of the chronic myeloproliferative disorders (E5487)
Autor:
Barbara W. Grant, Janice P. Dutcher, Martin M. Oken, John M. Bennett, John M. Kirkwood, Peter H. Wiernik, Haesook T. Kim, Arthur I. Radin, James A. Stewart, Richard G. Hahn
Publikováno v:
Cancer. 98:100-109
BACKGROUND In vitro and clinical data suggest a therapeutic role for α2 interferon (IFN) in the treatment of the chronic myeloproliferative disorders. Accordingly, a multiinstitutional, Phase II trial of IFN in patients with agnogenic myeloid metapl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06ebeba6b8bd8760ebe2abb8347792e6
https://doi.org/10.1002/cncr.11486
https://doi.org/10.1002/cncr.11486
Autor:
Kathleen J. Propert, Jonathan Fleischmann, Richard G. Hahn, J. Edson Pontes, George Wilding, Donald L. Trump, Edward M. Messing, Judith Manola, E. David Crawford
Publikováno v:
Journal of Clinical Oncology. 21:1214-1222
Purpose: To evaluate the role of adjuvant interferon alfa after complete resection of locally extensive renal cell carcinoma. Patients and Methods: A total of 283 eligible patients with pT3–4a and/or node-positive disease were randomly assigned aft
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ace58797ec1bbf17ad52477b59e24585
https://doi.org/10.1200/jco.2003.02.005
https://doi.org/10.1200/jco.2003.02.005
Autor:
Richard G. Hahn, Lawrence H. Einhorn, Paul Elson, Richard D. Williams, Patrick J. Loehrer, Robert Dreicer, Craig R. Nichols
Publikováno v:
Journal of Clinical Oncology. 12:483-488
PURPOSE This multicenter cooperative group phase I/II trial evaluated the toxicity and efficacy of escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) with recombinant human granulocyte colony-stimulating factor (rhG-CS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2846ad2d1c4e5482db78bfe779fa8dd4
https://doi.org/10.1200/jco.1994.12.3.483
https://doi.org/10.1200/jco.1994.12.3.483
Autor:
Paul Chervenick, Michael J. O'Connell, Janet Andersen, Richard G. Hahn, Stephanie Gregory, Leo I. Gordon, Joseph Mazza
Publikováno v:
Cancer. 71:464-470
Background The epidophyllotoxin VM 26 has been shown to have single-agent activity in patients with diffuse aggressive lymphoma. In an attempt to determine its activity in combination with other agents known to be effective in lymphoma, a Phase II tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1cdee733ae43a1e4ed8ab23440a3e13f
https://doi.org/10.1002/1097-0142(19930115)71:2<464::aid-cncr2820710230>3.0.co
https://doi.org/10.1002/1097-0142(19930115)71:2<464::aid-cncr2820710230>3.0.co
Autor:
Richard G. Hahn, Roscoe F. Morton, Shreyaskumar Patel, James E. Krook, Donald I. Twito, James A. Mailliard, Terry M. Therneau, John A. Laurie, Harold E. Windschitl
Publikováno v:
Cancer. 69:1440-1444
One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomyc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3fb20ffcfdbf3eec39e7c662358110d2
https://doi.org/10.1002/1097-0142(19920315)69:6<1440::aid-cncr2820690622>3.0.co
https://doi.org/10.1002/1097-0142(19920315)69:6<1440::aid-cncr2820690622>3.0.co
Publikováno v:
New England Journal of Medicine. 326:519-523
The combination of streptozocin and fluorouracil has become the standard therapy for advanced islet-cell carcinoma. However, doxorubicin has also been shown to be active against this type of tumor, as has chlorozotocin, a drug that is structurally si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47e7dca624e01c148bdda8194d9393b5
https://doi.org/10.1056/nejm199202203260804
https://doi.org/10.1056/nejm199202203260804
Autor:
Fernando J. Quevedo, Richard G. Hahn
Publikováno v:
Mayo Clinic Proceedings. 75:666-668
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38b5d31923e307e363785a0ec50cb430
https://doi.org/10.1016/s0025-6196(11)64610-7
https://doi.org/10.1016/s0025-6196(11)64610-7
Autor:
Carol M. Van Haelst‐Pisani, Richard G. Hahn, John H. Edmonson, Herbert M. Reiman, Jan C. Buckner, Daniel J. Schaid
Publikováno v:
Cancer. 68:2354-2358
To assess whether chemosensitivity in metastatic soft tissue sarcoma (STS) is influenced by the histologic grade of the tumor, the authors retrospectively analyzed tumor responses to doxorubicin-based chemotherapy in four prospective studies conducte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a28cf7ea16f9b7bcbc65684c4389d6d
https://doi.org/10.1002/1097-0142(19911201)68:11<2354::aid-cncr2820681104>3.0.co
https://doi.org/10.1002/1097-0142(19911201)68:11<2354::aid-cncr2820681104>3.0.co